Despite substantial improvement of the overall survival of patients with MEN1, gastroenteropancreatic neuroendocrine tumors, malignant nonfunctioning pancreatic neuroendocrine tumors in particular (25, 28, 29), remain associated with increased morbidity and mortality. This evidence concerns the gene MEN1 and neuroendocrine neoplasm.